Activity 5: SCS Biomarkers

 

Background/Aim:

Neuropathic pain has until recently not been classified as a disease itself, but rather as a symptom caused by other diseases. This condition is complicated because even when the underlying reason is treated and healed the pain can still remain in the patient. Today, there is no standardized clinical classification for neuropathic pain. The major reason for this is the lacking knowledge of the pathophysiological mechanisms causing the pain. The poor clinical classification makes the prevalence of neuropathic pain difficult to estimate. However, it is believed to occur in at least 2-4% of Sweden’s population. Due to the insufficient classification and understanding of the disease, there are no efficient drugs available. The most commonly used are antidepressants, antiepileptics or opiates. However, these drugs only reduce the pain sensation and can give serious side effects. One alternative treatment is Spinal Cord Stimulation (SCS), where the pain is reduced or blocked by electrical nerve stimulation. Despite the success of SCS, little is known about the mechanism behind the pain reduction. The aim of this project is to compare the neurochemical patterns of cerebrospinal fluid from neuropathic pain patients during pain and during pain relief with SCS.

 

 

 

 

 

Project leader

 

 

 

Participants:

 

  • Jonas Bergquist (UU)
  • Marcus Sjödin (UU)
  • Kim Kultima (UU)
  • Konstantin Artemenko (UU)
  • Torsten Gordh (UAS)
  • Anne-Li Lind (UAS)
  • Odd-Geir Berge (AZ)
  • Anders Wåhlstedt (UU)

 

 

PARTNERS
Uppsala Berzelii Technology Centre for Neurodiagnostics | Email info@berzelii.uu.se